RxDoctor Payments Data

Zainab Bundu

Family · Laurel, MDNPI 1508384116

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 52 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$549
  • Vertos Medical, Inc.$205
  • Scilex Pharmaceuticals Inc.$110
  • IBSA Pharma Inc.$88
  • Nevro Corp.$50
  • Biodelivery Sciences International, Inc.$40
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$1,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$168,845
Medicare patients
274
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen971$26,373
Lidocaine114$15,497
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$13,942
OxycontinOxycodone Hcl40$11,649
Xtampza ErOxycodone Myristate23$7,853
Oxycodone Hcl384$5,508
Diclofenac Sodium72$5,291
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen175$3,764
Gabapentin285$3,463
Morphine Sulfate ErMorphine Sulfate159$3,246
Pregabalin145$2,964
Buprenorphine14$2,795
Duloxetine Hcl146$2,378
Naloxone Hcl35$2,187
Tizanidine Hcl245$1,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$549$7,85323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →